PI3K信号通路在结直肠癌中的作用

国际肿瘤学杂志››2016,Vol. 43››Issue (8): 631-633.doi:10.3760/cma.j.issn.1673422X.2016.08.018

PI3K信号通路在结直肠癌中的作用

王豪,张庆玲

510515 广州，南方医科大学南方医院病理科南方医科大学第一临床医学院（王豪）；南方医科大学南方医院病理科南方医科大学基础医学院病理学系（张庆玲）

出版日期:2016-08-08发布日期:2016-07-05
通讯作者:张庆玲，Email: zqllc8@126.com E-mail:zqllc8@126.com
基金资助:

国家自然科学基金（81272760； 81472712）

PI3K signaling pathway in colorectal cancer

Wang Hao, Zhang Qingling

Department of Pathology, Nanfang Hospital, First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

Online:2016-08-08Published:2016-07-05
Contact:Zhang Qingling, Email: zqllc8@126.com E-mail:zqllc8@126.com
Supported by:

National Natural Science Foundation of China（81272760； 81472712）

摘要/Abstract

摘要：结直肠癌(CRC)的早期症状隐匿，多数患者在诊断时已经发生转移。化疗与靶向药物的联合治疗是目前治疗转移性CRC的主要策略，在CRC中高频出现异常激活的磷脂酰肌醇-3-激酶（PI3K）信号通路与CRC的发生发展有着十分密切的关系，对CRC的诊断与治疗具有重要的价值。

王豪,张庆玲. PI3K信号通路在结直肠癌中的作用[J]. 国际肿瘤学杂志, 2016, 43(8): 631-633.

Wang Hao, Zhang Qingling. PI3K signaling pathway in colorectal cancer[J]. Journal of International Oncology, 2016, 43(8): 631-633.

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting［J］. Nat Rev Cancer, 2015, 15(1): 7-24. DOI: 10.1038/nrc3860. ［3］ Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer［J］. Int J Cancer, 2007, 121(8): 1771-1778. DOI: 10.1002/ijc.22890. ［4］ Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage Ⅲ colon cancer intergroup trial［J］. J Natl Cancer Inst, 2013, 105(23): 1789-1798. DOI: 10.1093/jnci/djt298. ［5］ Kaur J, Sanyal SN. PI3kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac［J］. Tumour Biol, 2010, 31(6): 623-631. DOI: 10.1007/s13277-010-0078-9. ［6］ Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival［J］. N Engl J Med, 2012, 367(17): 1596-1606. DOI: 10.1056/NEJMoa1207756. ［7］ Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal antiinflammatory drug therapy in colorectal cancer［J］. J Clin Oncol, 2013, 31(34): 4297-4305. DOI: 10.1200/JCO.2013.50.0322. ［8］ Van Cutsem E, Khne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colo-rectal cancer: updated analysis of overall survival according to tumor K-RAS and BRAF mutation status［J］. J Clin Oncol, 2011, 29(15): 2011-2019. DOI: 10.1200/JCO.2010.33.5091. ［9］ SartoreBianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies［J］. Cancer Res, 2009, 69(5): 1851-1857. DOI: 10.1158/0008-5472.CAN-08-2466. ［10］ Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents［J］. Clin Cancer Res, 2013, 19(3): 657-667. DOI: 10.1158/1078-0432.CCR-11-1446. ［11］ Zhu YF, Yu BH, Li DL, et al. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases［J］. World J Gastroenterol, 2012, 18(28): 3745-3751. DOI: 10.3748/wjg.v18.i28.3745. ［12］ Wang G, Wang F, Ding W, et al. April induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway［J］. PLoS One, 2013, 8(1): e55298. DOI: 10.1371/journal.pone.0055298. ［13］ Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers［J］. J Surg Oncol, 2015, 111(7): 905-910. DOI: 10.1002/jso.23895. ［14］ Bendell JC, Rodon J, Burris HA, et al. Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors［J］. J Clin Oncol, 2012, 30(3): 282-290. DOI: 10.1200/JCO.2011.36.1360. ［15］ Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2012, 18(15): 4173-4182. DOI: 10.1158/1078-0432.CCR-12-0714. ［16］ Sarker D, Ang JE, Baird R, et al. Firstinhuman phase I study of pictilisib (GDC0941), a potent panclass I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2015, 21(1): 77-86. DOI: 10.1158/1078-0432.CCR-14-0947. ［17］ Roper J, Richardson MP, Wang WV, et al. The dual PI3K/mTOR inhibitor NVPBEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wildtype colorectal cancer［J］. PLoS One, 2011, 6(9): e25132. DOI: 10.1371/journal.pone.0025132. ［18］ Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patientderived xenografts of RASmutant colorectal carcinomas［J］. Clin Cancer Res, 2012, 18(9): 2515-2525. ［19］ Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer［J］. J Clin Oncol, 2010, 28(6): 1075-1083. DOI: 10.1200/JCO.2009.25.3641. ［20］ Yap TA, Yan L, Patnaik A, et al. Firstinman clinical trial of the oral panAKT inhibitor MK2206 in patients with advanced solid tumors［J］. J Clin Oncol, 2011, 29(35): 4688-4695. DOI: 10.1200/JCO.2011.35.5263. ［21］ Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition［J］. Sci Signal, 2009, 2(67): pe24. DOI: 10.1126/scisignal.267pe24. ［22］ Wolpin BM, Ng K, Zhu AX, et al. Multicenter phase Ⅱ study of tivozanib (AV951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer［J］. Oncologist, 2013, 18(4): 377-378. DOI: 10.1634/theoncologist.2012-0378. ［23］ Spindler KL, Sorensen MM, Pallisgaard N, et al. Phase Ⅱ trial of temsirolimus alone and in combination with irinotecan for K-RAS mutant metastatic colorectal cancer: outcome and results of K-RAS mutational analysis in plasma［J］. Acta Oncol, 2013, 52(5): 963970. DOI: 10.3109/0284186X.2013.776175. ［24］ Altomare I, Hurwitz H. Everolimus in colorectal cancer［J］. Expert Opin Pharmacother, 2013, 14(4): 505-513. DOI: 10.1517/14656566.2013.770473. ［25］ Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dualtargeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer［J］. Clin Cancer Res, 2012, 18(8): 2316-2325. DOI: 10.1158/1078-0432.CCR-11-2381.

[1]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	岳红云, 张百红.肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[7]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[8]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺.结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[9]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[10]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[11]	陶红, 殷红, 罗宏, 陶佳瑜.靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[12]	王熙, 吴川清.结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[13]	高一钊, 刘洋, 刘秋龙, 邢金良.循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[14]	何哲锋, 吴燚阳, 李振军, 应晓江.炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[15]	赵莹, 张革红.AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.